Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Daily Nevirapine to Prevent Mother to Infant Transmission of HIV Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Daily Nevirapine to Prevent Mother to Infant Transmission of HIV conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Daily Nevirapine to Prevent Mother to Infant Transmission of HIV Clinical research trials and Daily Nevirapine to Prevent Mother to Infant Transmission of HIV medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Daily Nevirapine to Prevent Mother to Infant Transmission of HIV. Daily Nevirapine to Prevent Mother to Infant Transmission of HIV Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Daily Nevirapine to Prevent Mother to Infant Transmission of HIV clinical trial. Participants frequently get the best healthcare available for their Daily Nevirapine to Prevent Mother to Infant Transmission of HIV condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.

Home > "D" Clinical Trials Conditions > Daily Nevirapine to Prevent Mother to Infant Transmission of HIV

Daily Nevirapine to Prevent Mother to Infant Transmission of HIV



Daily Nevirapine to Prevent Mother to Infant Transmission of HIV

For Condition: HIV Infections
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: Infants who are breast-fed by HIV infected mothers have an increased risk of becoming infected with HIV. Standard therapy for the prevention of HIV infections in infants included zidovudine (ZDV) prior to the onset of labor, a single dose of nevirapine (NVP) for women during labor, and a single dose of NVP for newborns given 72 hours after birth. This study will determine if giving low dose daily NVP to breastfed infants of HIV infected mothers, in addition to standard therapy, will be more effective than standard therapy alone at preventing HIV infections in these infants.
Details: This study will evaluate the safety and effectiveness of adding daily infant NVP to standard prevention measures to decrease vertical transmission of HIV. According to current statistics from the study site, approximately 70% of the pregnant HIV infected women in this study will have begun antenatal ZDV prior to the initiation of NVP at labor. The remaining 30% of the HIV infected women enrolled in this trial will have been previously undiagnosed. These women will be diagnosed with HIV infection either at the time they present to the delivery room in stage 1 of labor or immediately postpartum if they present for delivery late in labor and cannot provide informed consent for HIV screening prior to delivery. All infants will receive the standard does of NVP at 72 hours postpartum. Infants will then be randomized to receive either daily NVP and a daily multivitamin (MVI) or a daily MVI alone. Infants will take NVP/MVI or MVI alone during Weeks 2 to 6 postpartum. The primary outcome measure is infant HIV infection rates at 6 months. Two additional related cohorts of women will be followed for comparison: 1) an equal number of HIV uninfected women and their children will be enrolled for comparison of postpartum morbidity and mortality; and 2) consenting HIV infected women and their children who choose not to enroll in the clinical trial or are ineligible because they are not breastfeeding will be enrolled in an ancillary cohort.
Eligibility:
Study Type:  Interventional, Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria for Pregnant or Postpartum Mothers - HIV infected - Planning to breastfeed - Able to tolerate oral drugs and available for 12 months of postpartum follow-up Exclusion Criteria - Significant physical or emotional distress - Infant with serious or life threatening disease or severe fetal abnormality - Obstetrical complications affecting maternal health - Prior antiretroviral drugs (except antenatal ZDV or intrapartum NVP)
Total Enrollment: 1800

Location and Contact Information:

Overall Study Official:
RobertBollinger,  Principal Investigator,  Johns Hopkins University

BJ Medical College *Recruiting*
Pune,  , 
India
Recruiting Mridula  Phadke 91-20-553-8962


Additional Information:
Study ID Numbers:  5R01AI045462-04; 
Study Start Date: August 2002
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00061321

Other Hiv Infections Studies:
1. Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients with Persistent Generalized Lymphadenopathy

2. Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success with Protease Inhibitor-Containing HAART Regimen(s)

3. Growth Hormone Treatment of Children with HIV-Associated Growth Failure

4. A Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus

5. The Safety and Effectiveness of Ribavirin in the Early Stages of HIV-Infection

Related Studies:

Other HIV Infections Clinical Trials
Other Clinical Trials
Other Pune Clinical Trials

Daily Nevirapine to Prevent Mother to Infant Transmission of HIV
Modify your Search

  Other HIV Infections Clinical Trials
  Other Clinical Trials
  Other Pune Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103